HAEM5:Breast implant-associated anaplastic large cell lymphoma - Revision history

Richard.Glen at 18:37, 3 February 2026

2026-02-03T18:37:43Z

Richard.Glen: Removed redirect to BRST5:Breast implant-associated anaplastic large cell lymphoma

2026-02-03T18:35:54Z

Removed redirect to BRST5:Breast implant-associated anaplastic large cell lymphoma

← Older revision		Revision as of 13:35, 3 February 2026
Line 1:		Line 1:
	~~#REDIRECT~~[[~~BRST5~~:~~Breast implant-associated anaplastic large cell lymphoma~~]]		]\n[[Category:Diseases B]]"}}}

Richard.Glen: Redirected page to BRST5:Breast implant-associated anaplastic large cell lymphoma

2026-02-03T18:30:12Z

Redirected page to BRST5:Breast implant-associated anaplastic large cell lymphoma

Show changes

Bailey.Glen at 17:11, 3 July 2025

2025-07-03T17:11:22Z

← Older revision		Revision as of 12:11, 3 July 2025
Line 36:		Line 36:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:31, 25 May 2025

2025-05-25T21:31:32Z

← Older revision		Revision as of 16:31, 25 May 2025
Line 171:		Line 171:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 237:		Line 237:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 281:		Line 281:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:07, 25 May 2025

2025-05-25T20:07:07Z

← Older revision		Revision as of 15:07, 25 May 2025
Line 51:		Line 51:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|Seroma-associated anaplastic large cell lymphoma
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 17:33, 24 March 2025

2025-03-24T17:33:48Z

← Older revision		Revision as of 12:33, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Breast implant-associated anaplastic large cell lymphoma}}		{{DISPLAYTITLE:Breast implant-associated anaplastic large cell lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 15:		Line 14:

	Cedars-Sinai Medical Center		Cedars-Sinai Medical Center

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T22:18:09Z

Removed old template contents

Show changes

Bailey.Glen at 18:42, 10 February 2025

2025-02-10T18:42:18Z

Show changes

Bailey.Glen at 18:14, 10 February 2025

2025-02-10T18:14:12Z

← Older revision		Revision as of 13:14, 10 February 2025
Line 76:		Line 76:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Clinical Features\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*Pain, swelling around implant<ref name=":3">{{Cite journal\|last=D\|first=Lazzeri\|last2=T\|first2=Agostini\|last3=G\|first3=Bocci\|last4=G\|first4=Giannotti\|last5=G\|first5=Fanelli\|last6=Ag\|first6=Naccarato\|last7=R\|first7=Danesi\|last8=M\|first8=Tuccori\|last9=M\|first9=Pantaloni\|date=2011\|title=ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity\|url=https://pubmed.ncbi.nlm.nih.gov/21729665/\|language=en\|pmid=21729665}}</ref>		*Pain, swelling around implant<ref name=":3">{{Cite journal\|last=D\|first=Lazzeri\|last2=T\|first2=Agostini\|last3=G\|first3=Bocci\|last4=G\|first4=Giannotti\|last5=G\|first5=Fanelli\|last6=Ag\|first6=Naccarato\|last7=R\|first7=Danesi\|last8=M\|first8=Tuccori\|last9=M\|first9=Pantaloni\|date=2011\|title=ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity\|url=https://pubmed.ncbi.nlm.nih.gov/21729665/\|language=en\|pmid=21729665}}</ref>
Line 83:		Line 83:
	*Extracapsular extension to form a solid mass of tumor cells possible<ref name=":3" />		*Extracapsular extension to form a solid mass of tumor cells possible<ref name=":3" />

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Sites of Involvement==		==Sites of Involvement==
Line 112:		Line 115:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Immunophenotype\|The content below was from the old template. Please incorporate above.}}</blockquote>

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 126:		Line 129:
	\|}		\|}

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Chromosomal Rearrangements (Gene Fusions)==		==Chromosomal Rearrangements (Gene Fusions)==
Line 150:		Line 156:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Chromosomal Rearrangements (Gene Fusions)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*Not described		*Not described

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>

Line 161:		Line 170:
	* Individual Region Genomic Gain/Loss/LOH		* Individual Region Genomic Gain/Loss/LOH
	* Characteristic Chromosomal Patterns		* Characteristic Chromosomal Patterns
	* Gene Mutations (SNV/INDEL)}}		* Gene Mutations (SNV/INDEL)}}</blockquote>

	'''THIS SECTION IS REALLY FOR THE DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC SIGNIFICANCE OF THE MOLECULAR CHANGES FOUND IN THIS ENTITY. YOU CAN KEEP THE WORK YOU HAVE DONE BUT PERHAPS MOVE IT TO "OTHER INFORMATION" SECTION?'''		'''THIS SECTION IS REALLY FOR THE DIAGNOSTIC, PROGNOSTIC, AND THERAPEUTIC SIGNIFICANCE OF THE MOLECULAR CHANGES FOUND IN THIS ENTITY. YOU CAN KEEP THE WORK YOU HAVE DONE BUT PERHAPS MOVE IT TO "OTHER INFORMATION" SECTION?'''
Line 180:		Line 189:


	<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}<ref>{{Cite journal\|last=Mw\|first=Clemens\|last2=Ed\|first2=Jacobsen\|last3=Sm\|first3=Horwitz\|date=2019\|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)\|url=https://pubmed.ncbi.nlm.nih.gov/30715173/\|language=en\|pmid=30715173}}</ref><ref>{{Cite journal\|last=Mc\|first=Ferrufino-Schmidt\|last2=Lj\|first2=Medeiros\|last3=H\|first3=Liu\|last4=Mw\|first4=Clemens\|last5=Kk\|first5=Hunt\|last6=C\|first6=Laurent\|last7=J\|first7=Lofts\|last8=Mb\|first8=Amin\|last9=S\|first9=Ming Chai\|date=2018\|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/29194092/\|language=en\|pmid=29194092}}</ref><ref name=":0" /></blockquote>		<blockquote class='blockedit'>{{Box-round\|title=Unassigned References\|The following referenees were placed in the header. Please place them into the appropriate locations in the text.}}</blockquote><ref>{{Cite journal\|last=Mw\|first=Clemens\|last2=Ed\|first2=Jacobsen\|last3=Sm\|first3=Horwitz\|date=2019\|title=2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)\|url=https://pubmed.ncbi.nlm.nih.gov/30715173/\|language=en\|pmid=30715173}}</ref><ref>{{Cite journal\|last=Mc\|first=Ferrufino-Schmidt\|last2=Lj\|first2=Medeiros\|last3=H\|first3=Liu\|last4=Mw\|first4=Clemens\|last5=Kk\|first5=Hunt\|last6=C\|first6=Laurent\|last7=J\|first7=Lofts\|last8=Mb\|first8=Amin\|last9=S\|first9=Ming Chai\|date=2018\|title=Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/29194092/\|language=en\|pmid=29194092}}</ref><ref name=":0" /><blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
			</blockquote>
	</blockquote>		</blockquote>
	==Individual Region Genomic Gain / Loss / LOH==		==Individual Region Genomic Gain / Loss / LOH==
Line 229:		Line 244:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genomic Gain/Loss/LOH\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*N/A		*N/A

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Characteristic Chromosomal Patterns==		==Characteristic Chromosomal Patterns==
Line 257:		Line 275:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Characteristic Chromosomal Aberrations / Patterns\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*N/A		*N/A

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Gene Mutations (SNV / INDEL)==		==Gene Mutations (SNV / INDEL)==
Line 296:		Line 317:


	<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Gene Mutations (SNV/INDEL)\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*JAK1 and STAT3 mutation (variable pattern leads to activation)<ref>{{Cite journal\|last=P\|first=Blombery\|last2=Er\|first2=Thompson\|last3=K\|first3=Jones\|last4=Gm\|first4=Arnau\|last5=S\|first5=Lade\|last6=Jf\|first6=Markham\|last7=J\|first7=Li\|last8=A\|first8=Deva\|last9=Rw\|first9=Johnstone\|date=2016\|title=Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/27198716/\|language=en\|doi=10.3324/haematol.2016.146118\|pmc=PMC5060038\|pmid=27198716}}</ref><ref>{{Cite journal\|last=A\|first=Di Napoli\|last2=P\|first2=Jain\|last3=E\|first3=Duranti\|last4=E\|first4=Margolskee\|last5=W\|first5=Arancio\|last6=F\|first6=Facchetti\|last7=B\|first7=Alobeid\|last8=F\|first8=Santanelli di Pompeo\|last9=M\|first9=Mansukhani\|date=2018\|title=Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A\|url=https://pubmed.ncbi.nlm.nih.gov/27859003/\|language=en\|pmid=27859003}}</ref>		*JAK1 and STAT3 mutation (variable pattern leads to activation)<ref>{{Cite journal\|last=P\|first=Blombery\|last2=Er\|first2=Thompson\|last3=K\|first3=Jones\|last4=Gm\|first4=Arnau\|last5=S\|first5=Lade\|last6=Jf\|first6=Markham\|last7=J\|first7=Li\|last8=A\|first8=Deva\|last9=Rw\|first9=Johnstone\|date=2016\|title=Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/27198716/\|language=en\|doi=10.3324/haematol.2016.146118\|pmc=PMC5060038\|pmid=27198716}}</ref><ref>{{Cite journal\|last=A\|first=Di Napoli\|last2=P\|first2=Jain\|last3=E\|first3=Duranti\|last4=E\|first4=Margolskee\|last5=W\|first5=Arancio\|last6=F\|first6=Facchetti\|last7=B\|first7=Alobeid\|last8=F\|first8=Santanelli di Pompeo\|last9=M\|first9=Mansukhani\|date=2018\|title=Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A\|url=https://pubmed.ncbi.nlm.nih.gov/27859003/\|language=en\|pmid=27859003}}</ref>
Line 303:		Line 324:
	'''PUT IN THE TABLE FROM THE TEMPLATE, SO THE FREQUENCY OF THESE MUTATIONS AND THEIR SIGNIFICANCE CAN BE ENTERED.'''		'''PUT IN THE TABLE FROM THE TEMPLATE, SO THE FREQUENCY OF THESE MUTATIONS AND THEIR SIGNIFICANCE CAN BE ENTERED.'''

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Epigenomic Alterations==		==Epigenomic Alterations==
Line 328:		Line 352:
	\|}		\|}

	<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}		<blockquote class='blockedit'>{{Box-round\|title=v4:Genes and Main Pathways Involved\|The content below was from the old template. Please incorporate above.}}</blockquote>

	*JAK/STAT activation<ref name=":5">{{Cite journal\|last=Kim\|first=Won Seog\|date=2017-11-30\|title=Faculty Opinions recommendation of Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.\|url=http://dx.doi.org/10.3410/f.725957551.793539732}}</ref><ref name=":1" />		*JAK/STAT activation<ref name=":5">{{Cite journal\|last=Kim\|first=Won Seog\|date=2017-11-30\|title=Faculty Opinions recommendation of Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.\|url=http://dx.doi.org/10.3410/f.725957551.793539732}}</ref><ref name=":1" />
	*MYC/TP53 dysregulation<ref name=":5" /><ref name=":1" />		*MYC/TP53 dysregulation<ref name=":5" /><ref name=":1" />

			<blockquote class="blockedit">
			<center><span style="color:Maroon">'''End of V4 Section'''</span>
			----
	</blockquote>		</blockquote>
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==